Galderma Laboratories, L.P. today announced the results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopustular (inflammatory) rosacea. The data were presented at a Late-Breaking session of the 72nd annual meeting of the American Academy of Dermatology (AAD). The results of the studies, in which 910 subjects applied ivermectin 1% cream once daily for 12 weeks, demonstrate that ivermectin is safe and effective.